CFM
MXCT icon

Catalyst Funds Management’s MaxCyte MXCT Stock Holding History

Catalyst Funds Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.9K Buy
+61,700
New +$61.5K ﹤0.01% 628
2025
Q1 		– Sell
-17,700
Closed -$73.6K – 544
2024
Q4 		$73.6K Buy
+17,700
New +$66.9K 0.02% 275

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Catalyst Funds Management's MXCT Position: Q2 2026 in Review

Catalyst Funds Management opened a new position in MaxCyte (MXCT) in Q2 2026: 61,700 shares worth $75.9K. The stake represents ﹤0.01% of the portfolio and ranks #628 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in MXCT as recently as Q4 2024.

Catalyst Funds Management first reported a position in MXCT in Q4 2024 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Catalyst Funds Management held 61,700 shares of MaxCyte worth $75.9K as of Q2 2026.
  • MaxCyte was a new Catalyst Funds Management position in Q2 2026.
  • MaxCyte made up ﹤0.01% of Catalyst Funds Management's portfolio in Q2 2026, its #628 holding.
  • Catalyst Funds Management first reported a position in MaxCyte in Q4 2024 and has held it in 2 quarters since.
  • 123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.